Abstract: A conjugate comprising a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, characterised in that the linker includes at least two ˜(CH2—CH2—O—)˜ units within a ring, said ring being attached via a single tethering atom within the ring to the rest of the linker, or said ring being attached via two or more tethering atoms within the ring to the rest of the linker at a single point.

Abstract: A magnetic field within a magnetic resonance (MR) imaging system (300) is measured. The MR system includes a magnet (304) with an imaging zone (308), a radio-frequency transceiver (316), and a magnetic field probe (322) located within the imaging zone. The magnetic field probe includes a fluorine sample (404) including any one of the following: a fluoroelastomer (700), a fluorine containing ionic liquid (600), and a solution of a fluorine containing compound. The field probe further includes an antenna (406) for manipulating the magnetic spins of the fluorine sample and for receiving fluorine magnetic resonance data from the fluorine sample. The antenna is connected to the radio-frequency transceiver. The method includes acquiring (100, 200) the fluorine magnetic resonance data using the magnetic resonance imaging system and calculating (102, 206) a magnetic field strength (344) using the fluorine magnetic resonance data.

Abstract: A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.

Abstract: The present invention encompasses an antithrombotic nanoparticle.

Abstract: The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (CB1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the CB1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

Abstract: This invention relates to methods and systems for providing chemical and/or biological materials. Thus we describe a method of providing a chemical or biological material in a quantized form, the method comprising: preparing an emulsion comprising a plurality of microdroplets each holding a controlled amount of said material; storing said chemical or biological material in said microdroplets in said emulsion; transferring a portion of said emulsion microdroplets to a container for transportation; transporting said container to a user of said material, wherein said user receives said material in a quantized form in said microdroplets of said emulsion; and de-emulsifying said received microdroplets containing said material in quantized form to extract said material for subsequent use.

Abstract: The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

Abstract: The present invention relates to the synthesis and use of a novel trifluorinated bile acid analogue, that being, CA-sar-TFMA which is useful as an imaging probe, diagnostic agent or contrast agent and is resistant to bacterial deconjugation, wherein the trifluorinated bile acid analogue can be used as a 19F MRI tracer exhibiting an increased half-life due to its resistance to choloylglycine hydrolase.

Abstract: The present invention provides methods of detecting soluble amyloid ? using curcumin-derived near infrared (NIR) imaging probes. Upon interacting with soluble amyloid ?, these probes undergo a range of changes, qualifying them as “smart” probes. In addition, the invention provides methods of detecting soluble amyloid ? by positron emission tomography (PET), magnetic resonance imaging (MRI) and multimodal imaging based on the curcumin-derived NIR imaging probes and derivatives thereof.

Abstract: Magnetic resonance (MR) imaging typically has excellent spatial resolution, but relatively poor temporal resolution. In contrast, positron emission tomography (PET) typically has excellent temporal resolution, but poor spatial resolution relative to MR. Resultantly, it is advantageous to use combined PET-MR imaging sequences to create hybrid or enhanced images that reap the benefits of both modalities. A contrast agent (80) that includes both a PET tracer (82) and MR contrast enhancement (86) can be used in such a combined modality setting. The contrast agent (80) also includes a targeting system (84) that allows the contrast agent (80) to pool in a region of interest.

Abstract: A phantom for medical imaging instrumentation, the phantom including a first hydrogel matrix, said matrix containing additives for simulating the optical and acoustic properties of a living organ or tissue. In the phantom, the additives include Indian ink or haemoglobin, silica powder and titanium dioxide powder. The phantom may contain a tumor simulator in solid or liquid form. It may also comprise several hydrogel matrices, each matrix including additives in different concentrations depending on the organ or tissue simulated. A method of producing the phantom includes one or more freeze-thaw cycles for optimizing the characteristics of the phantom.

Abstract: The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

Abstract: Magnetic resonance imaging contrast agents that include a plurality of gas vesicles configured to associate with a noble gas are provided. Also provided are magnetic resonance imaging methods that include administering to a subject a contrast agent that includes a plurality of gas vesicles, obtaining a magnetic resonance data of a target site of interest, and analyzing the data to produce a magnetic resonance image of the target site. The subject contrast agents and methods find use in magnetic resonance imaging applications.

Abstract: The invention relates to an oil-in-water nanoemulsion for MRI, including: an aqueous phase, a fluorinated phase including at least one fluorinated oil, a surfactant at the interface between the aqueous and fluorinated phases, the surfactant comprising: at least one amphiphilic targeting ligand, at least one amphiphilic lipid, and at least one diblock or triblock fluorophilic compound, as well as to the use thereof as a contrast agent.

Abstract: Provided are compositions containing an emulsion containing a perfluorinated compound, as well as methods for preparation of the compositions. Also provided are formulations containing a complex of oxygen-17 and the emulsion compositions. Additionally provided are methods for the preparation of the formulations as well as kits containing the formulations. Further provided are methods of use of the formulations in imaging of tissues using a magnetic resonance imaging system.

Abstract: The present invention relates to fluorinated glutamic acid (glutamate) and glutamine derivatives wherein the fluorine atom is 19F. The glutamic acid (glutamate) and glutamine derivatives are compound(s) of general Formula I, which encompasses all possible diastereoisomers and/or enantiomere derivatives or mixtures thereof.

Abstract: In magnetic resonance imaging (MRI), selected magnetic dipoles in a subject are aligned with a main magnetic field for later manipulation, and signals received after such manipulations are used to create image representations of the subject. One drawback is that even powerful magnetic fields can only align a very small percentage of dipoles in the region of the field. Electromagnetic radiation endowed with orbital angular momentum (OAM) aligns dipoles along the direction of travel of the radiation, but at a much higher percentage; as high as 100% of the dipoles in the region can be aligned. Resultantly, resonance signals emanating from the region are several orders of magnitude stronger than signals emanated using traditional MRI techniques. All electromagnetic radiation, including visible light can be endowed with OAM and used to hyperpolarize a region of interest.

Abstract: At least one embodiment of the invention relates to bone marrow precursor cells or bone marrow cells of a patient, the cells labeled with at least one contrast agent suitable for an imaging method, for use in an imaging method for diagnosing a metastasizing cancer, wherein the local accumulation of the labeled precursor cells or bone marrow cells indicates the presence of a metastasizing tumor growth. At least one embodiment also relates to a method for imaging a metastasizing tumor tissue in a patient, wherein a) bone marrow precursor cells or bone marrow cells are extracted from a patient, b) these precursor cells or bone marrow cells are labeled with at least one contrast agent suitable for an imaging method, c) the precursor cells or bone marrow cells thus labeled are retransplanted or reinjected into the patient, and d) the presence of metastasizing tumor cells is depicted with an imaging method.

Abstract: The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

Abstract: The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.

Abstract: Methods and systems are described for determining, in a patient that suffers from a mood disorder (e.g., depression), a propensity of the patient to manifest reduced symptoms or levels of indicators of the mood disorder in response to a psychiatric treatment. This can involve determining levels of a marker (e.g., a metabolite) indicative of a brain bioenergetic state of the patient that is predictive of whether the patient will response favorably to an antidepression treatment. Such bioenergetic state markers, tending to normalize in response to antidepression therapy, can include, e.g., a pH, a magnesium level, and a phosphorus level. Brain levels of such markers can be determined by, e.g., 31P MRS.

Abstract: The disclosure provides, in part, fluorocarbon imaging reagents and methods for image-guided treatment and/or diagnosis of a subject with a condition associated with an inflammatory response in an internal organ. The disclosure additionally provides methods for image-guided treatment of myocardial infarction (MI) in a subject.

Abstract: The present invention generally relates to nonionic x-ray contrast media formulations, radiological compositions containing such agents and methods for x-ray visualization utilizing such compositions. The invention especially relates to injectable radiological compositions for x-ray visualization comprising a pharmaceutically acceptable vehicle and a mixture of a monomer, being a triiodo-substituted benzene nucleus, and a dimer, being two linked triiodo-substituted benzene nuclei, such that the mixture demonstrates favorable properties.

Abstract: The present invention relates to agents capable of binding to myelin basic protein in a subject. Also provided are methods for the detection of myelin-associated neuropathy comprising identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, administering to a subject an agent that binds specifically to myelin basic protein, and determining myelination in the subject by detecting the agent present in the subject. A kit containing the agent or its derivatives for use in detecting myelin basic protein is also provided.

Abstract: A magnetic resonance examination system comprises an RF-system for inducing resonance in polarized dipoles and receiving magnetic resonance signals from an object to be examined. A thermometry module dervies a temperature distribution of the object to be examined from the magnetic resonance signals. The magnetic resonance examination system further comprises a photonic-based hyperpolarization device with a photonic source for emitting electromagnetic radiation, a moder converter, such as a phase hologram to impart orbital angular momentum to the electromagnetic radiation and via spatial filter to select from the phase hologram a diffracted photonic beam endowed with orbital angular momentum for polarizing the dipoles via transferred orbital angular momentum.

Abstract: The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for 18F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs or toxins. More preferably, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment, using a click chemistry reaction involving cyclooctyne, nitron or azide reactive moieties. In most preferred embodiments, the click chemistry reaction occurs in vivo. In vivo click chemistry is not limited to 18F labeling but can be used for delivering a variety of therapeutic and/or diagnostic agents.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula (I), or formula (II); wherein X is OH, C1-C6 alkoxyl, 18F, or 19F; Y and Z are independently selected from a C1-C6 alkyl, CpC6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H, X is not OH.

Abstract: The present invention relates to methods for myelin basic protein detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the agent, and determining myelination in the subject by detecting binding to myelin basic protein. Methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using an agent with specific binding to myelin basic protein are also provided as is a kit containing the agent or its derivatives for use in detecting myelin basic protein.

Abstract: Methods for the synthesis and use of functionalized, substituted naphthalenes are described. The functionalized, substituted naphthalenes display useful properties including liquid crystals and fluorescence properties, such as solvatochromatic fluorescence, with high quantum yields, Stoke's shift, and show emission maxima that are significantly red-shifted.

Abstract: Disclosed is a carrier for the local, targeted administration of a hydrophobic drug. The hydrophobic drug is rendered in to a hydrophilic prodrug thereof, and is contained in the lumen of a thermosensitive liposome or polymersome. Upon administration of the carrier, heat can be applied at the locus where the drug is to be released. After release of the prodrug, it will be activated so as to turn into the active drug.

Abstract: Diagnostic methods for in vivo and ex vivo detection of oncolytic virus infection of tumors in a subject are provided. The diagnostic methods employ imaging agents that detect macrophage or inflammatory cells, such perfluorocarbon (PFC) imaging agents, to detection of inflammation associated with oncolytic virus administration, and, thereby detect tumors and cancers. Combinations and kits for use in the practicing the methods also are provided.

Abstract: This invention relates to determining the compliance of a subject receiving dietary supplementation with uridine or a uridine source. Specifically, the invention relates to the use of MRS for measuring an increase in brain compounds resulting from dietary supplementation with uridine or a uridine source.

Abstract: The present invention relates to amphiphilic polymers, and micelles and compositions comprising the same, and their use in a variety of biological settings, including imaging, targeting drugs, or a combination thereof for diagnostic and therapeutic purposes.

Abstract: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.

Abstract: Systems and methods for generating MRI images the lungs and/or airways of a subject using a medical grade gas mixture comprises between about 20-79% inert perfluorinated gas and at least about 20.5% oxygen gas. The images are generated using acquired 19F magnetic resonance image (MRI) signal data associated with the perfluorinated gas and oxygen mixture.

Abstract: The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

Abstract: A method of using a fluorinated polymer having a glass transition temperature below 40 C as a contrast agent in 19F magnetic resonance imaging (MRI) of a solid object, said solid object comprising said contrast agent. The invention relates to a solid object comprising a structural component and an imaging component, wherein the imaging component is at least one fluorinated polymer. The invention relates to a method for 19F MRI in solid state using a contrast agent comprising a fluorinated polymer as well as a method for in vivo visualizing a scaffold. It further relates to a method for in vivo monitoring the degradation of a solid object in time, wherein the degradation is monitored in time by using 19F MRI to visualize the solid object, and wherein the amount of degradation of the solid object is determined based on the decrease in the visibility of the amount of 19F.

Abstract: Described is the use of perfluoro-t-butyl cyclohexane in a contrast agent for molecular imaging, notably F MRI. Particularly, the perfluoro-t-butyl cyclohexane is present in the form of an aqueous emulsion of nanoparticles comprising the perfluoro compound as a core, and an emulsifying agent, such as a phospholipid, as a shell. The shell can be functionalized with other moieties that play a role in imaging, notably ligands for targeted binding and/or contrast agents or labels with a view to other imaging modalities. The latter particularly refers to 1H MRI contrast agents as well as radiolabels for SPECT.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula (I), or formula (II); wherein X is OH, C1-C6 alkoxyl, 18F, or 19F; Y and Z are independently selected from a C1-C6 alkyl, CpC6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H, X is not OH.

Abstract: The present invention provides multiple modalities for detecting LOX-1. More particularly, an imaging composition is provided that allows for the in vivo imaging of atherosclerotic plaque.

Abstract: The present invention relates to novel MAO-B binding compounds and methods for measuring effects of the compounds, by measuring changes of MAO-B levels in living patients. More specifically, the present invention relates to use of the compounds of this invention as therapeutic agents for inhibition of MAO-B activity as well as a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study MAO-B levels in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel MAO-B binding compounds as diagnostic, as we a therapeutic, agents. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted azabenzoxazole derivatives, compositions, and therapeutic uses and processes for making such compounds.

Abstract: Described herein are nanoemulsions comprising (1) at least one fluoro ether and (2) a block copolymer comprising a hydrophilic block and hydrophobic block, wherein the nanoemulsion comprises a therapeutic agent in the nanoemulsion. The nanoemulsions are stable and are excellent drug delivery devices for ultrasound-mediated, image guided drug delivery. Also described herein are methods for using the nanoemulsions to treat tumors and cancers as well as using them as imaging agents.

Abstract: Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a 19F MR contrast agent. Preferably, the carrier also acts as a contrast enhancement agent for MRI based on the principle of Chemical Exchange-dependent Saturation Transfer (CEST). To this end the shell encloses a cavity that comprises a paramagnetic chemical shift reagent, a pool of proton analytes, and the 19F contrast agent, and wherein the shell allows diffusion of the proton analytes.

Abstract: At least one embodiment of the invention relates to bone marrow precursor cells or bone marrow cells of a patient, the cells labeled with at least one contrast agent suitable for an imaging method, for use in an imaging method for diagnosing a metastasizing cancer, wherein the local accumulation of the labeled precursor cells or bone marrow cells indicates the presence of a metastasizing tumor growth. At least one embodiment also relates to a method for imaging a metastasizing tumor tissue in a patient, wherein a) bone marrow precursor cells or bone marrow cells are extracted from a patient, b) these precursor cells or bone marrow cells are labeled with at least one contrast agent suitable for an imaging method, c) the precursor cells or bone marrow cells thus labeled are retransplanted or reinjected into the patient, and d) the presence of metastasizing tumor cells is depicted with an imaging method.

Abstract: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.

Abstract: The present invention relates to a multimodal imaging method using a nano-emulsion comprising optical nano-particles and perfluorocarbons, and more particularly, to a method of obtaining multimodal images using a nano-emulsion consisted of perfluorocarbons for multispectral magnetic resonance imaging (MRI) and nano-particles for multicolor fluorescent detection. In the multimodal imaging method, various multispectral MRI images and multicolor fluorescent rays can be obtained by varying the kind and combination of perfluorocarbons and the kind and combination of optical nano-particles, so that multiplexed analysis is possible. Accordingly, the multimodal imaging method can be applied to various fields, including biological and medical fields in which studies on cell molecular imaging has been conducted.

Abstract: The present invention relates to a transition metal complex represented by Formula (I) or salts thereof, or to a ligand represented by Formula (H) or salts thereof, wherein X represents a transition metal, preferably Pt, and methods for their use and preparation. In particular, the invention relates to compounds which may possess useful therapeutic activity in treating amyloid diseases, and in particular, Alzheimer's disease. The invention also relates to the use of these compounds in methods of therapy, and diagnosis, and the manufacture of medicaments as well as compositions containing these compounds.

Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.

Abstract: The present invention is directed to an implantable device comprising a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and one or more bioactive agents. The invention is further directed to methods of using and the process of preparing, the implantable device.

Abstract: Disclosed are cannabimimetic aminoalkylindole compounds and methods for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoids. The disclosed compounds may include radioactive atoms. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological effect in an animal or individual, to treat a condition in an animal or individual and for use in radioimaging.